Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 13/20 | 0.40 |
| ▸ | TYK2 | P29597 | 11/20 | 0.40 |
| ▸ | JAK2 | O60674 | 10/20 | 0.40 |
| ▸ | JAK1 | P23458 | 7/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | CASP1 | P29466 | 4/20 | 0.36 |
| ▸ | CASP7 | P55210 | 4/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31637530 | 0.67 | CCND1 (0.49) | — | |
| SCHEMBL4828611 | 0.67 | CCND1 (0.49) | — | |
| SCHEMBL4714882 | 0.67 | RPS6KB1 (0.53) | — | |
| SCHEMBL22860491 | 0.64 | NUAK1 (0.50) | CYP1A2HSD17B10ALDH1A1CASP1CASP7 | |
| SCHEMBL22860290 | 0.64 | NUAK1 (0.50) | CYP1A2HSD17B10ALDH1A1CASP1CASP7 | |
| SCHEMBL29508806 | 0.64 | NUAK1 (0.50) | CYP1A2HSD17B10ALDH1A1CASP1CASP7 | |
| SCHEMBL22165942 | 0.63 | NUAK1 (0.59) | — | |
| SCHEMBL22860694 | 0.63 | NUAK1 (0.56) | — | |
| SCHEMBL29508796 | 0.63 | NUAK1 (0.59) | — | |
| SCHEMBL29508775 | 0.63 | NUAK1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | disclosed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | disclosed |
| EP-1490367-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | JAK3 86/4885TYK2 245/4885JAK2 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.